Physician profile

Neeharik Mareedu

Nephrology (Internal Medicine) · Cumberland, MD

NPI 1467834556

$591.50

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$108.05
Education$2.66

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $208.26 2021-2023 Farxiga
Vifor Pharma, INC. $197.76 2021-2022
Mallinckrodt Hospital Products INC. $55.22 2021
Abbvie INC. $39.71 2021
Opko Pharmaceuticals, LLC $36.71 2021
Bayer Healthcare Pharmaceuticals INC. $35.22 2023
Baxter Healthcare $15.96 2022
Travere Therapeutics, INC. $2.66 2023

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Neeharik Mareedu

$591.50

in general payments reported 2019-2025

Years
2021-2023
Top company
Astrazeneca Pharmaceuticals LP

https://glasscript.com/doctor/4217294/neeharik-mareedu

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.